Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMX-200 in focal segmental glomerulosclerosis
ISRCTN72772236Phase 3Recruiting
- Sponsor
- Dimerix
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of repagermanium in focal segmental glomerulosclerosis (FSGS) (3 arms), sponsored by Dimerix. Primary endpoints: Percent change in urine protein creatinine ratio at week 35, Slope of estimated glomerular filtration rate to week 104 and 1 more. Started Feb 2022; status: recruiting.
02
Drugs
repagermanium
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on ISRCTN72772236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72772236.